AXL and non-small cell lung carcinoma: In EGFR TKI-resistant tumor xenografts, the expression level of AXL was found to be elevated, and inhibition of AXL recovered the sensitivity to EGFR-TKI, which implies that activation of AXL is essential for acquired resistance to EGFR-TKI in NSCLC [25].